Post-Ischemic Treatment of Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Myocardial Ischemia/Reperfusion Injury

Post-Ischemic Treatment of Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Myocardial Ischemia/Reperfusion Injury

Myocardial ischemia/reperfusion (I/R) injury is a major cause of mortality and morbidity worldwide. Among factors contributing to I/R injury, proteolytic enzymes could also cause cellular injury, expand the injured area and induce inflammation, which then lead to cardiac dysfunction. Therefore, prot...

Full description

Bibliographic Details
Main Authors: Podsawee Mongkolpathumrat, Anusak Kijtawornrat, Eakkapote Prompunt, Aussara Panya, Nipon Chattipakorn, Stephanie Barrère-Lemaire, Sarawut Kumphune
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Biomedicines
Subjects:
ischemic heart disease
ischemia/reperfusion injury
secretory leukocyte protease inhibitor (SLPI)
cardioprotection
post-ischemic treatment
Online Access:https://www.mdpi.com/2227-9059/9/4/422

Internet

https://www.mdpi.com/2227-9059/9/4/422

Similar Items